Role of Tolvaptan in congestive heart failure patients: A novel therapeutic approach

Role of Tolvaptan in congestive heart failure patients: A novel therapeutic approach

Bibliographic Details
Main Authors:	T.D. Shah, S.T. Varghese, R.L. Kamath, M.N. Bhat, N.D. Pai, R.U. Bhat, P.K. Kamath
Format:	Article
Language:	English
Published:	Elsevier 2014-11-01
Series:	Indian Heart Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S0019483214004957

Similar Items

Correlation of duration of diabetes with severity of coronary artery disease in patients with type 2 Diabetes Mellitus
by: T.D. Shah, et al.
Published: (2014-11-01)

Congenital coronary artery to pulmonary artery fistula: An unseen Villain
by: T.D. Shah, et al.
Published: (2014-11-01)

Factors associated with normal coronary arteries in patients with type 2 Diabetes Mellitus for more than 10 years of duration
by: M.P. Srinivasan, et al.
Published: (2014-11-01)

Clinical effects of adding tolvaptan to intravenous furosemide in patients with congestive heart failure
by: Mahoto Kato, et al.
Published: (2017-01-01)

Tolvaptan, hyponatremia, and heart failure
by: Zmily HD, et al.
Published: (2011-03-01)

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction
by: Shinichi Nonin, et al.
Published: (2018-12-01)

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.
by: Mei-Yi Wu, et al.
Published: (2017-01-01)

Correction: Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.
by: Mei-Yi Wu, et al.
Published: (2019-01-01)

A NEW APPROACH TO DETECT CONGESTIVE HEART FAILURE USING DETRENDED FLUCTUATION ANALYSIS OF ELECTROCARDIOGRAM SIGNALS
by: CHANDRAKAR KAMATH
Published: (2015-02-01)

Tolvaptan
by: Bharath Rangarajan, et al.
Published: (2014-01-01)

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
by: Savina Nodari, et al.
Published: (2010-05-01)

Tolvaptan: A Novel Diuretic in Heart Failure Management
by: Hilman Zulkifli Amin, et al.
Published: (2016-07-01)

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure
by: Teruhiko Imamura, et al.
Published: (2016-01-01)

A RISK STRATIFICATION SYSTEM TO DISCRIMINATE CONGESTIVE HEART FAILURE PATIENTS USING MULTI-VALUED COARSE-GRAINING LEMPEL-ZIV COMPLEXITY
by: CHANDRAKAR KAMATH
Published: (2015-01-01)

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure
by: Hiromi Kin, et al.
Published: (2020-08-01)

Tolvaptan for treatment of iatrogenic hyponatremia
by: Dhaval Shukla
Published: (2016-01-01)

Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis
by: Chunbin Wang, et al.
Published: (2017-06-01)

Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction
by: Shunsuke Tamaki, et al.
Published: (2020-06-01)

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan
by: Kensuke Fujioka, et al.
Published: (2019-01-01)

Long-Term Effects and Prognosis in Acute Heart Failure Treated with Tolvaptan: The AVCMA Trial
by: Satoshi Suzuki, et al.
Published: (2014-01-01)

Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan
by: Yusuke Yamazaki, et al.
Published: (2021-09-01)

The management of polycystic liver disease by tolvaptan
by: Tsuneo Takenaka, et al.
Published: (2020-01-01)

Tolvaptan and its potential in the treatment of hyponatremia
by: Y Howard Lien, et al.
Published: (2008-10-01)

Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial
by: Elangovan Shanmugam, et al.
Published: (2016-04-01)

Tolvaptan add‐on therapy in patients with acute heart failure: A systematic review and meta‐analysis
by: Xiandu Luo, et al.
Published: (2020-06-01)

Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions
by: Purav R. Bhatt, et al.
Published: (2014-11-01)

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
by: Hiroki Mizuno, et al.
Published: (2017-07-01)

Is Intravenously Administered Tolvaptan Mighty Like Triton?
by: Nochioka, K.
Published: (2022)

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)
by: Tien M.H. Ng, et al.
Published: (2020-08-01)

STUDY ON SERUM ELECTROPHORETIC PATTERN IN CONGESTIVE CARDIAC FAILURE
by: R P Singh, et al.
Published: (2003-01-01)

Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF)　- A Phase III, Multicenter, Open-Label Trial
by: Hirano, T., et al.
Published: (2022)

Congestion Games with Failures
by: Penn, Michal, et al.
Published: (2011)

Congestive heart failure
by: Burton, G. E.
Published: (1946)

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?
by: Mahabala C, et al.
Published: (2013-03-01)

Peritoneal dialysis in congestive heart failure
by: Abirami Krishnan, et al.
Published: (2017-04-01)

The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia
by: Fatih Kahraman, et al.
Published: (2015-04-01)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
by: Tomomi Kogiso, et al.
Published: (2018-12-01)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
by: Takuya Adachi, et al.
Published: (2021-05-01)

Congestion in heart failure, a prominent role in pathophysiology, and a therapeutic goal
by: Jorge Rubio-Gracia, et al.
Published: (2021-01-01)

Hypopituitarism presenting as congestive heart failure
by: S Giri, et al.
Published: (2017-01-01)